Corporate Social Responsibility
– Dr Anji Reddy Founder-Chairman
Dr Reddy’s Laboratories
“In one of our foundations, I decided that we should go into providing good pathogen-free drinking water, at a price at which the poorest of the poor in this country can afford. The result is that we are able to give 12 litres of that water,” shared Dr Anji Reddy, Founder-Chairman, Dr Reddy’s Laboratories, while accepting the award for Corporate Social Responsibility by the Honourable Union Minister of Science & Technology and Earth Sciences, Kapil Sibal. “I have taken a firm decision that by the end of 2020 every Indian should be able to drink that water, and then probably half of our antibiotics business will be gone,” joked Reddy.
The award is instituted by Express Pharma to honour the companies that have truly made an effort to extend finances, knowledge, technical know-how and medicinal help to the community, and according to Express Pharma, E&Y and the jury panel, Dr Reddy’s Laboratories seemed to fit the profile very well.
Amongst many initiatives taken by the company, Sparsh is a programme that extends specific services to patients, including compassionate drugs. It aims to touch the lives of people who not only suffer from the disease, but also those who are under the burden of expensive treatment. The Patient Assistance Programme is the first initiative under Sparsh, which extended Glioz, a treatment for brain tumour to 780 programmes. Dr Reddy’s Foundation for Health Educator, implemented under the Naandi Foundation and guided under the Chairman Dr K Anji Reddy, has trained over 150 patient educators in the area of metabolic disorders. The company has also invested in a non-profit partner, Dr Reddy’s Foundation on Sustainable Livelihoods and Quality education initiatives for the deprived.
According to data released by WHO/Clinton Foundation, one out of every three HIV patients is receiving treatment from a Cipla produced anti-AIDS drugs; indicating its role in curing AIDS. In addition, the company also partners with Clinton Foundation for pediatric/AIDS Initiative covering more than 45,000 HIV/AIDS infected children. The company contributes $3 million as a donation in form of subsidised drugs.
Extending its rather expensive cancer molecule to those who cannot afford it, Novartis has set up the Glivec International Patient Assistance Program (GIPA) to provide access to Glivec for patients who could not afford the drug and were not insured or reimbursed.
Striving to offer high quality ARVs at affordable cost, Ranbaxy became the first company in the world to develop and file for WHO pre-qualification for three drug ARV fixed dose combinations in dispersible tablet form for paediatric use.